



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbsilpa.com, Web: www.vbsilpa.com
CIN: L85110KA1987PLC008739

Date: 06 February 2026

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir/Madam,

Sub: - Shilpa announces the filing of ROTIGOTINE Transdermal System, USP, its FIRST TRANSDERMAL PATCH ANDA to the USFDA

Ref: - Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015,

This is to inform you that Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has filed its Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch USP, ANDA for US market, marking its first-ever transdermal patch submission to the U.S. Food and Drug Administration (USFDA).

This application submitted as an ANDA with USFDA is a generic version of the innovator product Neupro®. Shilpa's product is pharmaceutical and bioequivalent version of the reference product Neupro®. Shilpa's Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson's disease. The total addressable US market for Rotigotine is estimated at USD 112 million.

This Filing represents a significant milestone for the Company, being Shilpa Medicare's First transdermal patch dosage form, which is a complex dosage form to be filed in the US market. The once-daily, patient-friendly transdermal formulation ensures reproducible, sustained, and controlled release of medication, enhancing patient compliance. This submission has come from the Company's finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, located at Dobbaspet, Bengaluru, Karnataka. The facility is involved in manufacturing, packaging, labelling and testing of specialized finished dosage forms as oral dispersible/dissolving Films and Transdermal Patches.

This Unit of Shilpa is approved by Europe and USFDA and is engaged in the manufacture and testing of transdermal Systems and Oral Mouth Dissolving Films.



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

About Shilpa Medicare Limited

Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED) is a leading Indian pharmaceutical company focused on the development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa serves patients in over 80 countries. For more information, visit www.vbshilpa.com

This information is also available on the website at www.vbshilpa.com

This is for your information and records.

For SHILPA MEDICARE LIMITED

Ritu Tiwary

Company Secretary & Compliance Officer